An automated system for production of [sup 89]Zr

Wooten, A. Lake; Schweitzer, G. D.; Lawrence, L. A.; Madrid, Evelyn; Lapi, Suzanne E.

doi:10.1063/1.4773968

Cited by 7 publications

(6 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Zirconium-89 ( 89 Zr) provides good positron emission tomography (PET) spatial resolution, as it decays via positron emission with a low average energy (Eb þ , average ¼ 396 keV) and has a half-life of 3.27 days that matches the long biological half-life of antibodies. 46,47 Frequently, the radiolabeling of intact antibodies with 89 Zr is performed through the modification of a native lysine side chain with desferrioxamine-B (DFO). 47,48 Nevertheless, it has been suggested that this chelator is not considered ideal for satisfying the coordination sphere of the Zr 4þ cation, which can lead to the release of the radiometal from its chelator in rodent studies, leading to an accumulation in the bone.…”

Section: Intact Antibodiesmentioning

confidence: 99%

“…However, as 89 Zr emits high-energy (909 keV) gamma rays associated with a high branching ratio (99.0%) coupled with the 511 keV gamma ray (22% branching ratio) for PET, dosimetry is an important concern. 46 Laforest et al showed that 89 Zr-trastuzumab had high residence times in several organs, mainly in the liver, kidney, and heart muscle. The liver was determined to be the critical organ, with a dose of 1.63 mSv/MBq (6.02 rad/mCi) due to the highest uptake of 89 Zr-trastuzumab in this organ, as opposed to dose received from neighboring organs.…”

Section: Intact Antibodiesmentioning

confidence: 99%

See 1 more Smart Citation

Targeting HER2 in Nuclear Medicine for Imaging and Therapy

2018

View full text Add to dashboard Cite

Since its discovery, the human epidermal growth factor 2 (HER2) has been extensively studied. Presently, there are 2 standard diagnostic techniques to assess HER2 status in biopsies: immunohistochemistry and fluorescence in situ hybridization. While these techniques have played an important role in the treatment of patients with HER2-positive cancer, they both require invasive biopsies for analysis. Moreover, the expression of HER2 is heterogeneous in breast cancer and can change over the course of the disease. Thus, the degree of HER2 expression in the small sample size of biopsied tumors at the time of analysis may not represent the overall status of HER2 expression in the whole tumor and in between tumor foci in the metastatic setting as the disease progresses. Unlike biopsy, molecular imaging using probes against HER2 allows for a noninvasive, whole-body assessment of HER2 status in real time. This technique could potentially select patients who may benefit from HER2-directed therapy and offer alternative treatments to those who may not benefit. Several antibodies and small molecules against HER2 have been labeled with different radioisotopes for nuclear imaging and/or therapy. This review presents the most recent advances in HER2 targeting in nuclear medicine focusing on preclinical and clinical studies.

show abstract

Section: Intact Antibodiesmentioning

confidence: 99%

Section: Intact Antibodiesmentioning

confidence: 99%

Targeting HER2 in Nuclear Medicine for Imaging and Therapy

2018

View full text Add to dashboard Cite

show abstract

“…Berkeley, California, United States) at Washington University School of Medicine in St. Louis 82 (WUSM). Various methods (Table 1) were carried out by remotely-controlled automated modules inside of lead hot cells to separate the following isotope products from the corresponding bulk solid target material: 64 Cu (Kume et al, 2012;McCarthy et al, 1997), 76 Br (McCarthy et al, 1999Tolmachev et al, 1998), 86 Y (Avila-Rodriguez et al, 2008Yoo et al, 86 2005), and 89 Zr (Holland et al, 2009;Meijs et al, 1994;Wooten et al, 2012). Manganese-52 was produced by bombarding a natural Cr foil target with protons (Wooten et al, 2015), followed by digesting the Cr foil in hydrochloric acid with no further purification.…”

Section: Isotope Production 79mentioning

confidence: 99%

Calibration setting numbers for dose calibrators for the PET isotopes 52Mn, 64Cu, 76Br, 86Y, 89Zr, 124I

Wooten

Lewis

Szatkowski

et al. 2016

Applied Radiation and Isotopes

View full text Add to dashboard Cite

For PET radionuclides, the radioactivity of a sample can be conveniently measured by a dose calibrator. These devices depend on a "calibration setting number", but many recommended settings from manuals were interpolated based on standard sources of other radionuclide(s). We conducted HPGe gamma-ray spectroscopy, resulting in a reference for determining settings in two types of vessels containing one of several PET radionuclides. Our results reiterate the notion that in-house, experimental calibrations are recommended for different radionuclides and vessels.

show abstract

“…Although most PET radiometals are still at the research stage, automated separation modules are still useful for many of the same reasons, but principally to minimize dose to personnel. Several groups have published on custom-made automated modules for various radiometals, including 64 Cu [41][42][43][44] 89 Zr [48,49]. In this work, we have designed, built and commissioned a module that has performed the chemical separation of 89 Zr safely and routinely, at activities in excess of 50 mCi, with high radionuclidic purity and satisfactory ESA.…”

Section: +mentioning

confidence: 99%

Routine Production of 89Zr Using an Automated Module

et al. 2013

View full text Add to dashboard Cite

89Zr has emerged as a useful radioisotope for targeted molecular imaging via positron emission tomography (PET) in both animal models and humans. This isotope is particularly attractive for cancer research because its half-life (t 1/2 = 3.27 days) is well-suited for in vivo targeting of macromolecules and nanoparticles to cell surface antigens expressed by cancer cells. Furthermore, 89Zr emits a low-energy positron (E β+,mean = 0.40 MeV), which is favorable for high spatial resolution in PET, with an adequate branching ratio for positron emission (BR = 23%). The demand for 89 Zr for research purposes is increasing; however, 89Zr also emits significant gamma radiation (Γ 15 keV = 6.6 Rcm 2 /mCih), which makes producing large amounts of this isotope by hand unrealistic from a radiation safety standpoint. Fortunately, a straightforward method exists for production of Zr safely and routinely, at activities in excess of 50 mCi, with radionuclidic purity > 99.9% and satisfactory effective specific activity (ESA).

show abstract

An automated system for production of [sup 89]Zr

Cited by 7 publications

References 5 publications

Targeting HER2 in Nuclear Medicine for Imaging and Therapy

Targeting HER2 in Nuclear Medicine for Imaging and Therapy

Calibration setting numbers for dose calibrators for the PET isotopes 52Mn, 64Cu, 76Br, 86Y, 89Zr, 124I

Routine Production of 89Zr Using an Automated Module

Contact Info

Product

Resources

About